Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes marker negative sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Patients with myeloid malignancies \[e.g. myelodysplastic syndrome (MDS) or other diseases\], will be allowed to enroll to Master protocol if there is an available sub-study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek minimum 60 lat w momencie rozpoznania (lub 18+ lat w specjalnych grupach genetycznych)
- •Zdolność do zrozumienia informacji o badaniu i podpisania zgody
- •Grupa A: Pacjenci z nową diagnozą białaczki ostrych myeloidalnych, wcześniej nieleczeni (z wyjątkiem hydroksyureasu)
- •Grupa B: Pacjenci, u których białaczka wróciła po leczeniu lub nie odpowiada na leczenie
- •Pacjenci z innymi nowotworami szpiku kostnego (takie jak zespół mielodysplastyczny) też mogą uczestniczyć
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (31)
Mayo Clinic Arizona
Phoenix, United States
Mayo Clinic - Scottsdale
Scottsdale, United States
UCLA Ronald Reagan Medical Center
Los Angeles, United States
University of California, San Francisco
San Francisco, United States
University of Colorado
Denver, United States
University of Florida Health Shands Cancer Hospital
Gainesville, United States
Mayo Clinic Florida
Jacksonville, United States
Orlando Health Cancer Institute
Orlando, United States
Winship Cancer Institute of Emory University
Atlanta, United States
Georgia Cancer Center
Augusta, United States
Rush University Medical Center
Chicago, United States
University of Chicago
Chicago, United States
University of Kansas Clinical Research Center
Fairway, United States
Pikeville Medical Center
Pikeville, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, United States
Massachusetts General Hospital- Boston
Boston, United States
Mayo Clinic Minnesota
Rochester, United States
St. Louis University
St Louis, United States
Washington University in St. Louis
St Louis, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Univerisy of Rochester
Rochester, United States
UNC Hospitals, University of North Carolina at Chapel Hill
Chapel Hill, United States
University of Cincinnati Medical Center
Cincinnati, United States
Ohio State University
Columbus, United States
Oregon Health & Science University
Portland, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
Brown University Health
Providence, United States
University of Texas Southwest Medical
Dallas, United States
MD Anderson
Houston, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
WVU Health Sciences Center
Morgantown, United States
Trial contact
Ashley Yocum, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.